组织多肽特异性抗原的临床意义

杨柳

组织多肽特异性抗原的临床意义

杨柳

文章导航 > 国际放射医学核医学杂志 > 2003, 27 > 5: (216-218)

引用本文:

Citation:

组织多肽特异性抗原的临床意义

杨柳

434000 荆州市, 湖北省荆州市第一人民医院内分泌科

作者简介: 杨柳(1957-),男,主管技师,主要从事临床核医学研究。;

中图分类号: R446.62

Clinical value of tissue polypeptide specific antigen

YANG Liu

Department of Endocrinology, Jingzhou First People's Hospital, Jingzhou 434000, China
CLC number: R446.62

摘要: 恶性肿瘤的复发是患者高死亡率的重要因素之一,提高恶性肿瘤复发的早期诊断,是提高恶性肿瘤患者预后生存率的前提。组织多肽特异性抗原在恶性肿瘤复发的诊断上有着较为突出的优势。
- 组织多肽特异性抗原 /
- 恶性肿瘤 /
- 复发
Abstract: The high recurrence of malignant tumor is one of the important factors in mortality of the can-cer.The way to raise the rate of early diagnosis in recurrence of the malignant tumor is to raise the prognosis of survival rate.The tissue polypeptide specific antigen has its dominance in early diagnosis of the recurrence of the malignant tumor.
- tissue polypeptide specific antigen /
- malignant tumor /
- recurrence
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Rebhandl W, Rami B, Turbull J, et al. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Willms' tumour[J].Br J Cancer,1998,78(11): 1503-1506.
[2]	Senapad S, Neungton S, Thirapakawong C, et al. Predictive calue of the combined serum CA125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer[J]. Anticancer Res, 2000, 20(2B): 1297-1300.
[3]	Van Dalen A, Favier J, Baumgartner L, et al. Prognostic significance of CA125 and TPS levels after chemotherapy in ovarian cancer atients[J]. Anticancer Res, 1999, 19(4A): 2523-2526.
[4]	Tempfer C, Hefler L, Haeusler G, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients[J]. Int J Cancer, 1998, 79(3): 241-244.
[5]	Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA21-1 and carcinoem-bryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?[J]. Cancer, 1998, 82(10): 1850-1859.
[6]	Ho YJ, Hsieh JF, Tasi SC, et al. Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma[J]. Lung, 2000, 178(2): 75-80.
[7]	Slesak B, Harlozinska-Szmyrka A, Knast W, et al. Tissue polyopeptide specific antigen(TPS), a amrker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative studywith CA19-9[J]. Cancer, 2000, 89(1): 83-88.
[8]	Polito M, Minardi D, Recchioni A, et al. Serum markers for monitoring of prostatic carcinoma[J]. Prostate, 1997, 33(3): 208-216.
[9]	Suzuki S, Furukawa H, Tsuchiya A, et al. Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma[J]. Thyroid, 1999, 9(9): 921-925.

[1]	徐鑫 , 邓胜明 , 李继会 , 黄莹 , 张玮 . ¹⁸F-FDG PET/CT在胃癌复发及转移监测中的临床价值. 国际放射医学核医学杂志, 2019, 43(2): 125-131. doi: 10.3760/cma.j.issn.1673-4114.2019.02.006
[2]	刘英 , 陈龙华 , 巩湘浩 , 吕国士 . VEGF与肿瘤的放射治疗. 国际放射医学核医学杂志, 2003, 27(4): 183-186.
[3]	张悦 . ¹⁸F-氟脱氧葡萄糖PET和PET-CT在结直肠癌术后复发或转移中的应用价值. 国际放射医学核医学杂志, 2007, 31(1): 34-36.
[4]	王剑杰 , 张滨 , 马潞娜 , 田智勇 . ¹⁸F-FDG PET/CT 对急性白血病骨髓移植术后髓内复发灶的诊断价值. 国际放射医学核医学杂志, 2021, 45(8): 486-494. doi: 10.3760/cma.j.cn121381-202010022-00089
[5]	张静 , 陈畅 , 杨仪 , 章斌 . 分化型甲状腺癌术后持续性和（或）复发性颈部淋巴结转移的诊疗. 国际放射医学核医学杂志, 2022, 46(11): 692-696. doi: 10.3760/cma.j.cn121381-202202004-00241
[6]	范我 . 用于肿瘤治疗的放射性药物. 国际放射医学核医学杂志, 2004, 28(1): 21-25.
[7]	洪敏 , 张帅君 , 余道江 , 张舒羽 . 术后放疗在瘢痕疙瘩治疗中的研究进展. 国际放射医学核医学杂志, 2021, 45(3): 198-204. doi: 10.3760/cma.j.cn121381-202007019-00029
[8]	张伟 , 于丽娟 . ¹⁸F-FDG PET/CT与¹⁸F-FDG PET/MRI在卵巢癌临床应用中的进展. 国际放射医学核医学杂志, 2018, 42(5): 441-446. doi: 10.3760/cma.j.issn.1673-4114.2018.05.010
[9]	高骏 , 段玉清 , 于江 , 李祎亮 . 新型PET显像剂¹⁸F-FACBC在前列腺癌中的应用进展. 国际放射医学核医学杂志, 2017, 41(4): 288-293. doi: 10.3760/cma.j.issn.1673-4114.2017.04.010
[10]	赵德明 , 洪元康 . ¹²⁵I间质植入作为妇科恶性肿瘤复发的补救治疗. 国际放射医学核医学杂志, 1992, 16(4): 191-191.